...Christopher Grisham; Beth N. Peshkin; Lia Sorgen; Claudine Isaacs; Mary Kathleen Ladd; Aryana Jacobs; Savannah Binion; Mara Tynan; Emily Kuchinsky; Susan Friedman; Kathryn L. Taylor; Kristi Graves; Suzanne O’Neill; David Kim; Marc D. Schwartz Introduction: When a pathogenic BRCA1 or BRCA2 mutation...

...Haeseung Yi; Meghna S. Trivedi; Katherine D. Crew; Isaac Schechter; Paul Appelbaum; Wendy K. Chung; John P. Allegrante; Rita Kukafka Introduction: Although the prevalence of a pathogenic variant in the BRCA1 and BRCA2 genes is about 1:400 (0.25%) in the general population, the prevalence is as high...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Breast cancer Early-onset Genetic counseling BRCA1 BRCA2...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. BRCA1 BRCA2 Genetic testing Orthodox Jewish women Women...

... on different levels of exposure: (a) women who were randomized to culturally tailored (CTGC) and standard genetic counseling (SGC) to women who declined randomization (non-randomized group), (b) participants and non-participants in genetic counseling, and (c) BRCA1 and BRCA2 ( BRCA1/2) test result acceptors...